Cubist’s Zerbaxa Approval Marks Firm’s Second Novel Antibiotic In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
With only two weeks left in 2014, Cubist grabs another FDA approval for an antibiotic, this time to treat Gram-negative infections.